Fuller & Thaler Asset Management Inc. lowered its holdings in Baxter International Inc. (NYSE:BAX) by 68.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,194 shares of the medical instruments supplier’s stock after selling 9,000 shares during the period. Fuller & Thaler Asset Management Inc.’s holdings in Baxter International were worth $263,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also added to or reduced their stakes in the company. Baker Ellis Asset Management LLC acquired a new position in shares of Baxter International in the 2nd quarter valued at approximately $109,000. Acrospire Investment Management LLC grew its holdings in Baxter International by 71.3% during the 2nd quarter. Acrospire Investment Management LLC now owns 2,402 shares of the medical instruments supplier’s stock worth $145,000 after acquiring an additional 1,000 shares during the last quarter. Harvest Fund Management Co. Ltd grew its holdings in Baxter International by 8.4% during the 2nd quarter. Harvest Fund Management Co. Ltd now owns 2,928 shares of the medical instruments supplier’s stock worth $177,000 after acquiring an additional 226 shares during the last quarter. Captrust Financial Advisors bought a new stake in shares of Baxter International in the 2nd quarter valued at $188,000. Finally, Hutner Capital Management Inc. bought a new stake in shares of Baxter International in the 3rd quarter valued at $203,000. 83.59% of the stock is owned by institutional investors and hedge funds.
Shares of Baxter International Inc. (NYSE BAX) opened at $64.02 on Wednesday. Baxter International Inc. has a one year low of $43.13 and a one year high of $66.18. The company has a quick ratio of 2.22, a current ratio of 2.80 and a debt-to-equity ratio of 0.37. The stock has a market cap of $35,005.45, a price-to-earnings ratio of 26.55, a PEG ratio of 2.15 and a beta of 0.69.
Baxter International (NYSE:BAX) last posted its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $0.64 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.59 by $0.05. The company had revenue of $2.71 billion during the quarter, compared to analyst estimates of $2.66 billion. Baxter International had a net margin of 9.88% and a return on equity of 15.00%. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.56 earnings per share. research analysts expect that Baxter International Inc. will post 2.43 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, January 2nd. Investors of record on Friday, December 1st will be given a dividend of $0.16 per share. The ex-dividend date is Thursday, November 30th. This represents a $0.64 annualized dividend and a yield of 1.00%. Baxter International’s payout ratio is currently 34.41%.
A number of equities research analysts have recently commented on the stock. BidaskClub raised shares of Baxter International from a “buy” rating to a “strong-buy” rating in a research note on Monday, August 14th. Royal Bank Of Canada reiterated a “hold” rating and set a $66.00 target price on shares of Baxter International in a research report on Wednesday, November 22nd. Morgan Stanley boosted their target price on shares of Baxter International from $59.00 to $62.00 and gave the company an “equal weight” rating in a research report on Thursday, October 26th. Zacks Investment Research downgraded shares of Baxter International from a “buy” rating to a “hold” rating in a research report on Monday, October 16th. Finally, Cowen reiterated a “neutral” rating on shares of Baxter International in a research report on Friday, October 13th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $67.46.
In related news, Director Third Point Llc sold 5,000,000 shares of the stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $64.23, for a total transaction of $321,150,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.05% of the stock is currently owned by corporate insiders.
About Baxter International
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.